These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Progressive motor impairment from "critical" demyelinating lesions of the cervicomedullary junction. Jackson-Tarlton CS; Flanagan EP; Messina SA; Barakat B; Ahmad R; Kantarci OH; Weinshenker BG; Keegan BM Mult Scler; 2023 Jan; 29(1):74-80. PubMed ID: 36000479 [TBL] [Abstract][Full Text] [Related]
11. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096 [TBL] [Abstract][Full Text] [Related]
12. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055 [TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
14. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027 [TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Barakat B; Messina S; Nayak S; Kassa R; Sechi E; Flanagan EP; Kantarci O; Weinshenker BG; Keegan BM Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211052159. PubMed ID: 35047187 [TBL] [Abstract][Full Text] [Related]
17. Homogeneity of active demyelinating lesions in established multiple sclerosis. Breij EC; Brink BP; Veerhuis R; van den Berg C; Vloet R; Yan R; Dijkstra CD; van der Valk P; Bö L Ann Neurol; 2008 Jan; 63(1):16-25. PubMed ID: 18232012 [TBL] [Abstract][Full Text] [Related]
18. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice. Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532 [TBL] [Abstract][Full Text] [Related]
19. Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study). Pérez-Miralles F; Prefasi D; García-Merino A; Ara JR; Izquierdo G; Meca-Lallana V; Gascón-Giménez F; Martínez-Ginés ML; Ramió-Torrentà L; Costa-Frossard L; Fernández Ó; Moreno-García S; Medrano N; Maurino J; Casanova B Mult Scler Relat Disord; 2021 May; 50():102860. PubMed ID: 33647591 [TBL] [Abstract][Full Text] [Related]
20. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Karussis D J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]